Richard Ig Holt1,2, Daniel Hind3, Rebecca Gossage-Worrall3, Michael J Bradburn3, David Saxon4, Paul McCrone5, Tiyi A Morris5, Angela Etherington6, David Shiers7,8, Katharine Barnard9, Lizzie Swaby3, Charlotte Edwardson10, Marian E Carey11, Melanie J Davies10, Christopher M Dickens12, Yvonne Doherty11,13, Paul French7, Kathryn E Greenwood14,15, Sridevi Kalidindi16, Kamlesh Khunti11, Richard Laugharne17, John Pendlebury18, Shanaya Rathod19, Najma Siddiqi20,21, Stephen Wright22, Glenn Waller23,24, Fiona Gaughran25,26, Janette Barnett11, Alison Northern11. 1. Human Development and Health Academic Unit, Faculty of Medicine, University of Southampton, Southampton, UK. 2. University Hospital Southampton NHS Foundation Trust, Southampton, UK. 3. Clinical Trials Research Unit, University of Sheffield, Sheffield, UK. 4. School of Health and Related Research, University of Sheffield, Sheffield, UK. 5. King's Health Economics, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. 6. Independent service user consultant. 7. Psychosis Research Unit, Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK. 8. School of Health Sciences, Division of Psychology and Mental Health, University of Manchester, Manchester, UK. 9. Faculty of Health & Social Sciences, Bournemouth University, Poole, UK. 10. Diabetes Research Centre, University of Leicester, Leicester, UK. 11. Leicester Diabetes Centre, University Hospitals of Leicester, Leicester, UK. 12. Institute of Health Research, University of Exeter Medical School, Exeter, UK. 13. Psychological Medicine, York Teaching Hospital NHS Foundation Trust, York, UK. 14. Sussex Partnership NHS Foundation Trust, Worthing, UK. 15. School of Psychology, University of Sussex, Brighton, UK. 16. Rehabilitation and Recovery, South London and Maudsley NHS Foundation Trust, London, UK. 17. Research and Innovation, Cornwall Partnership NHS Foundation Trust, Redruth, UK. 18. Retired NHS community psychiatric nurse. 19. Research and Development, Southern Health NHS Foundation Trust, Southampton, UK. 20. Department of Health Sciences, Hull York Medical School, University of York, York, UK. 21. Bradford District Care NHS Foundation Trust, Bradford, UK. 22. Leeds and York Partnership NHS Foundation Trust, Leeds, UK. 23. Sheffield Health & Social Care NHS Foundation Trust, Sheffield, UK. 24. Department of Psychology, University of Sheffield, Sheffield, UK. 25. Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. 26. National Psychosis Unit and Research and Development Department, South London and Maudsley NHS Foundation Trust, London, UK.
Abstract
BACKGROUND: Obesity is twice as common in people with schizophrenia as in the general population. The National Institute for Health and Care Excellence guidance recommends that people with psychosis or schizophrenia, especially those taking antipsychotics, be offered a healthy eating and physical activity programme by their mental health care provider. There is insufficient evidence to inform how these lifestyle services should be commissioned. OBJECTIVES: To develop a lifestyle intervention for people with first episode psychosis or schizophrenia and to evaluate its clinical effectiveness, cost-effectiveness, delivery and acceptability. DESIGN: A two-arm, analyst-blind, parallel-group, randomised controlled trial, with a 1 : 1 allocation ratio, using web-based randomisation; a mixed-methods process evaluation, including qualitative case study methods and logic modelling; and a cost-utility analysis. SETTING:Ten community mental health trusts in England. PARTICIPANTS: People with first episode psychosis, schizophrenia or schizoaffective disorder. INTERVENTIONS:Intervention group: (1) four 2.5-hour group-based structured lifestyle self-management education sessions, 1 week apart; (2) multimodal fortnightly support contacts; (3) three 2.5-hour group booster sessions at 3-monthly intervals, post core sessions. Control group: usual care assessed through a longitudinal survey. All participants received standard written lifestyle information. MAIN OUTCOME MEASURES: The primary outcome was change in weight (kg) at 12 months post randomisation. The key secondary outcomes measured at 3 and 12 months included self-reported nutrition (measured with the Dietary Instrument for Nutrition Education questionnaire), objectively measured physical activity measured by accelerometry [GENEActiv (Activinsights, Kimbolton, UK)], biomedical measures, adverse events, patient-reported outcome measures and a health economic assessment. RESULTS: The trial recruited 414 participants (intervention arm: 208 participants; usual care: 206 participants) between 10 March 2015 and 31 March 2016. A total of 341 participants (81.6%) completed the trial. A total of 412 participants were analysed. After 12 months, weight change did not differ between the groups (mean difference 0.0 kg, 95% confidence interval -1.59 to 1.67 kg; p = 0.964); physical activity, dietary intake and biochemical measures were unchanged. Glycated haemoglobin, fasting glucose and lipid profile were unchanged by the intervention. Quality of life, psychiatric symptoms and illness perception did not change during the trial. There were three deaths, but none was related to the intervention. Most adverse events were expected and related to the psychiatric illness. The process evaluation showed that the intervention was acceptable, with participants valuing the opportunity to interact with others facing similar challenges. Session feedback indicated that 87.2% of participants agreed that the sessions had met their needs. Some indicated the desire for more ongoing support. Professionals felt that the intervention was under-resourced and questioned the long-term sustainability within current NHS settings. Professionals would have preferred greater access to participants' behaviour data to tailor the intervention better. The incremental cost-effectiveness ratio from the health-care perspective is £246,921 per quality-adjusted life-year (QALY) gained and the incremental cost-effectiveness ratio from the societal perspective is £367,543 per QALY gained. CONCLUSIONS: Despite the challenges of undertaking clinical research in this population, the trial successfully recruited and retained participants, indicating a high level of interest in weight management interventions; however, the STEPWISE intervention was neither clinically effective nor cost-effective. Further research will be required to define how overweight and obesity in people with schizophrenia should be managed. The trial results suggest that lifestyle programmes for people with schizophrenia may need greater resourcing than for other populations, and interventions that have been shown to be effective in other populations, such as people with diabetes mellitus, are not necessarily effective in people with schizophrenia. TRIAL REGISTRATION: Current Controlled Trials ISRCTN19447796. FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 65. See the NIHR Journals Library website for further project information.
RCT Entities:
BACKGROUND:Obesity is twice as common in people with schizophrenia as in the general population. The National Institute for Health and Care Excellence guidance recommends that people with psychosis or schizophrenia, especially those taking antipsychotics, be offered a healthy eating and physical activity programme by their mental health care provider. There is insufficient evidence to inform how these lifestyle services should be commissioned. OBJECTIVES: To develop a lifestyle intervention for people with first episode psychosis or schizophrenia and to evaluate its clinical effectiveness, cost-effectiveness, delivery and acceptability. DESIGN: A two-arm, analyst-blind, parallel-group, randomised controlled trial, with a 1 : 1 allocation ratio, using web-based randomisation; a mixed-methods process evaluation, including qualitative case study methods and logic modelling; and a cost-utility analysis. SETTING: Ten community mental health trusts in England. PARTICIPANTS: People with first episode psychosis, schizophrenia or schizoaffective disorder. INTERVENTIONS: Intervention group: (1) four 2.5-hour group-based structured lifestyle self-management education sessions, 1 week apart; (2) multimodal fortnightly support contacts; (3) three 2.5-hour group booster sessions at 3-monthly intervals, post core sessions. Control group: usual care assessed through a longitudinal survey. All participants received standard written lifestyle information. MAIN OUTCOME MEASURES: The primary outcome was change in weight (kg) at 12 months post randomisation. The key secondary outcomes measured at 3 and 12 months included self-reported nutrition (measured with the Dietary Instrument for Nutrition Education questionnaire), objectively measured physical activity measured by accelerometry [GENEActiv (Activinsights, Kimbolton, UK)], biomedical measures, adverse events, patient-reported outcome measures and a health economic assessment. RESULTS: The trial recruited 414 participants (intervention arm: 208 participants; usual care: 206 participants) between 10 March 2015 and 31 March 2016. A total of 341 participants (81.6%) completed the trial. A total of 412 participants were analysed. After 12 months, weight change did not differ between the groups (mean difference 0.0 kg, 95% confidence interval -1.59 to 1.67 kg; p = 0.964); physical activity, dietary intake and biochemical measures were unchanged. Glycated haemoglobin, fasting glucose and lipid profile were unchanged by the intervention. Quality of life, psychiatric symptoms and illness perception did not change during the trial. There were three deaths, but none was related to the intervention. Most adverse events were expected and related to the psychiatric illness. The process evaluation showed that the intervention was acceptable, with participants valuing the opportunity to interact with others facing similar challenges. Session feedback indicated that 87.2% of participants agreed that the sessions had met their needs. Some indicated the desire for more ongoing support. Professionals felt that the intervention was under-resourced and questioned the long-term sustainability within current NHS settings. Professionals would have preferred greater access to participants' behaviour data to tailor the intervention better. The incremental cost-effectiveness ratio from the health-care perspective is £246,921 per quality-adjusted life-year (QALY) gained and the incremental cost-effectiveness ratio from the societal perspective is £367,543 per QALY gained. CONCLUSIONS: Despite the challenges of undertaking clinical research in this population, the trial successfully recruited and retained participants, indicating a high level of interest in weight management interventions; however, the STEPWISE intervention was neither clinically effective nor cost-effective. Further research will be required to define how overweight and obesity in people with schizophrenia should be managed. The trial results suggest that lifestyle programmes for people with schizophrenia may need greater resourcing than for other populations, and interventions that have been shown to be effective in other populations, such as people with diabetes mellitus, are not necessarily effective in people with schizophrenia. TRIAL REGISTRATION: Current Controlled Trials ISRCTN19447796. FUNDING: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 22, No. 65. See the NIHR Journals Library website for further project information.
Authors: C Carswell; J V E Brown; J Lister; R A Ajjan; S L Alderson; A Balogun-Katung; S Bellass; K Double; S Gilbody; C E Hewitt; R I G Holt; R Jacobs; I Kellar; E Peckham; D Shiers; J Taylor; N Siddiqi; P Coventry Journal: BMC Psychiatry Date: 2022-07-19 Impact factor: 4.144
Authors: Nichole Goodsmith; Amy N Cohen; Anthony W P Flynn; Alison B Hamilton; Gerhard Hellemann; Nancy Nowlin-Finch; Alexander S Young Journal: Psychiatr Serv Date: 2021-01-12 Impact factor: 3.084
Authors: Stephen J Walters; Richard M Jacques; Inês Bonacho Dos Anjos Henriques-Cadby; Jane Candlish; Nikki Totton; Mica Teo Shu Xian Journal: Trials Date: 2019-09-13 Impact factor: 2.279
Authors: Rebecca Gossage-Worrall; Daniel Hind; Katharine D Barnard-Kelly; David Shiers; Angela Etherington; Lizzie Swaby; Richard I G Holt Journal: BMC Psychiatry Date: 2019-11-13 Impact factor: 3.630
Authors: Alexandra Burton; Kate Walters; Louise Marston; David Osborn Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2020-05-18 Impact factor: 4.328
Authors: Dandara Almeida Reis da Silva; Ludmila Santana de Almeida; Livia Lugarinho Correa; Rodrigo Fernandes Weyll Pimentel; Antonio Marcos Tosoli Gomes; Ana Gabriela Travassos; Adriana Mattos Viana; Monique Magnavita Borba da Fonseca Cerqueira; Marcio Costa de Souza; Anderson Reis de Sousa; Paulo José Bastos Barbosa; Julita Maria Freitas Coelho; Lucelia Batista Neves Cunha Magalhães; Argemiro D'Oliveira Júnior; Jorge Lopes Cavalcante Neto; Charles Souza Santos; Luiz Carlos Moraes França; Juliana de Lima Brandão; Livia Fajin de Mello Dos Santos; Helena Ferraz Gomes; Ellen Marcia Peres; Thais Regis Aranha Rossi; Kairo Silvestre Meneses Damasceno; Millena Conceição das Mercês; Sandra Lúcia Fernandes; Eline de Almeida Soriano; Isolda Prado de Negreiros Nogueira Maduro; Tatiana Santos Brandão; Amanda Cardoso Menezes; Amália Ivine Costa Santana; Magno Conceição das Merces Journal: Int J Environ Res Public Health Date: 2022-08-17 Impact factor: 4.614
Authors: Ryan Williams; Sagana Natkulasingam; Beatrice Tooke; Ella Webster; Alan Quirk; Veenu Gupta; Paul French; Jo Smith; Mike J Crawford Journal: BJPsych Bull Date: 2022-06